Effects of Pentoxifylline and Methylprednisolone Combined Therapy on Sarcoidosis
PDF
Cite
Share
Request
Clinical Study
VOLUME: 1 ISSUE: 1
P: 15 - 20
June 2000

Effects of Pentoxifylline and Methylprednisolone Combined Therapy on Sarcoidosis

1. Gazi University, Faculty of Medicine, Department of Pulmonary Medicine
2. Gazi University School of Medicine, Department of Pulmonary Diseases, Ankara, Turkey
3. Gazi University, Faculty of Medicine, Department of Pulmonary Medicine, Ankara
No information available.
No information available
Accepted Date: 06.10.2021
Online Date: 06.10.2021
Publish Date: 06.10.2021
PDF
Cite
Share
Request

Abstract

Sarcoidosis is a multisystem granulomatous disorder. Alveolar cells, in the course of sarcoidosis, produce TNF-a which is thought to play a pivotal role in granuloma formation. For patients with steroid complications, contraindications or resistance other alternative drugs have been evaluated. One of them is pentoxifylline (POF), which is shown to inhibit TNF-a production.This report is about the results of combined therapy of methylprednisolone and POF in 4 sarcoidosis patients. Threefrom (U/L) 52, 128, 55 to 45, 52, and 23 respectively. Diffusing capacity of the lung for carbon monoxide (DLCO) increased from (% predicted) 49, 81, 52 to 58, 85, 80 respectively. 67 Gallium uptake suppressed in all three responder patients.

Keywords:
Sarcoidosis, Pentoxifylline, Methylprednisolone of them improved significantly after 6 months’ therapy. All had radiological regression. Serum angiotensin converting enzyme levels decreased